New Study Suggests Ketamine May Be An Effective Treatment for Children with ADNP Syndrome
September 6, 2022
First-ever clinical trial for rare disorder that is a leading genetic cause of autism also identifies path for a ketamine clinical development program.
Study of More Than 150,000 People Identifies Genes Strongly Linked to Autism and Neurodevelopmental Disorders
August 17, 2022
Total of 252 genes cited, providing insights on how mutations might result in developmental disorder and potential targets for treatment.
Els for Autism Spring into Action Together (SIAT) Program Empowers Caregivers with Skills and Knowledge to Improve Social Communication in Toddlers and Young Children with Autism
July 1, 2022
The results of a pilot study, in collaboration with the Seaver Autism Center for Research and Treatment at Mount Sinai, are published in the Journal of Autism and Developmental Disorders (JADD).
Mount Sinai and Rumi Scientific Team Up to Advance Drug Discovery for Rare Genetic Disorders Tied to Autism
January 6, 2021
The Seaver Autism Center and Rumi Scientific initiate a pipeline to create high-throughput screening platforms to efficiently test thousands of therapeutic compounds for rare disorders with high risk of autism – starting with ADNP, DDX3X, and FOXP1 genes.
Epigenetic Changes in ADNP Syndrome, a Cause of Autism, Do Not Indicate Profound Presentation of the Disorder
August 5, 2020
Study Finds Epigenetic Signatures Show Little Correlation to Severity of Symptoms
Seaver Autism Center For Research and Treatment at Mount Sinai Launches First Drug Trial for ADNP Syndrome
July 7, 2020
Ketamine may provide hope for families affected by a rare disorder that is a leading genetic cause of autism
Mount Sinai to Accelerate Rare Disease Research Through a Grant from the Chan Zuckerberg Initiative
February 10, 2020
Grant supports parent-led DDX3X Foundation that selected the team at Seaver Autism Center as research and clinical partners
Largest Autism Sequencing Study to Date Identifies 102 Genes Associated With the Condition
January 23, 2020
For this study, an international team of researchers from more than 50 sites collected and analyzed more than 35,000 participant samples, including nearly 12,000 with ASD, the largest autism sequencing cohort to date.
Meta-Analysis Highlights Important Challenges In Cognitive Processing For Adults With Autism Spectrum Disorder Without Overall Intellectual Disability
January 2, 2019
Seaver Autism Center study results contribute to understanding of patterns of cognitive functioning in adults with autism and highlight the importance of a broader approach when studying cognition.
Four Studies by Mount Sinai Investigators Featured in Special Issue of Science Focused on Big Data
December 13, 2018
Genome-wide de novo risk score implicates promoter variation in autism spectrum disorder Joseph D. Buxbaum, PhD, Director of the Seaver Autism Center for Research and Treatment and Professor of Psychiatry, Neuroscience, and Genetics and Genomic Sciences.
- Common Medications Taken During Pregnancy Are Not Associated With Risk for Autism
October 31, 2018
Babies exposed in the womb to the majority of medications that target neurotransmitter systems, including typical targets of antidepressants and antipsychotic drugs, are not any more likely to develop autism than non-exposed babies.
- Mount Sinai Studies Selected as Top Research Advances of 2017 by Federal Advisory Committee on Autism
July 5, 2018
Five publications from The Seaver Autism Center for Research and Treatment at Mount Sinai were nominated as important advances in autism spectrum disorder (ASD) research by the Interagency Autism Coordinating Committee (IACC), a federal advisory committee that coordinates all ASD efforts within the Department of Health and Human Services concerning ASD, for their annual Summary of Advances report.
- The Seaver Autism Center for Research and Treatment at Mount Sinai Announces Clinical Trial of New Investigational Therapy for Phelan-McDermid Syndrome
May 7, 2018
The Seaver Autism Center for Research and Treatment at Mount Sinai announced today the start of patient enrollment in a new interventional study of an investigational therapy in the treatment of epilepsy associated with Phelan-McDermid syndrome.
- Mount Sinai of New York and Els for Autism Foundation Join Forces to Establish Research Institute at The Els Center of Excellence in Jupiter, Florida
April 2, 2018
The newly created Seaver Els Institute will bring together personalized education, clinical research and scientific investigation for individuals and families who are affected by autism spectrum disorder.
- The Seaver Center for Autism Research and Treatment Receives $2.78 Million Gift from the Beatrice and Samuel Seaver Foundation to Support Precision Medicine Research in Autism Spectrum Disorders
March 5, 2018
Trustees Hirschell E. Levine and John Cohen of the Beatrice and Samuel Seaver Foundation recently announced a $2.78 million gift to The Seaver Autism Center for Research and Treatment at Mount Sinai to support precision medicine research in autism spectrum disorders (ASD), including rare genetic causes of autism.